The American Society of Clinical Oncology's (ASCO) largest symposium, Gastrointestinal Tumors, was held in San Francisco, California from January 20-22, 2022. GI ASCO is a specialty oncology event that provides an opportunity to share the latest research and science in the prevention, diagnosis and interdisciplinary treatment of gastrointestinal cancers. The event featured a wide range of interdisciplinary topics of international interest, including: esophageal, gastric, pancreatic, small intestine, hepatobiliary, colorectal, rectal and anal canal cancers.
Exacte Labs participated, as a pharmacokinetics laboratory, in a study of Alofanib for the treatment of gastrointestinal cancer.
The clinical trial found that the drug helped stop gastric cancer in 68.4% of patients and resulted in a significant reduction in tumor mass, even at the initial dose (50 mg/m2) with a disease control duration of 18.5 months.
Alofanib is the first Russian targeted drug to enter clinical trials in oncology.
The results of the scientific work were presented at GI ASCO 2022 and selected for discussion with the chairman of the symposium, Professor Ian Chow from The Royal Marsden (UK).